U.S. Markets close in 5 hrs 20 mins

MetaStat, Inc. (MTST)


Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
1.350.00 (0.00%)
As of 3:41PM EDT. Market open.
People also watch
PSCOWEBBTIERFPMIMTSI
Full screen
Previous Close1.35
Open0.00
Bid0.00 x
Ask0.00 x
Day's Range0.00 - 0.00
52 Week Range
Volume0
Avg. Volume2,100
Market Cap6.36M
Beta0.61
PE Ratio (TTM)-0.64
EPS (TTM)N/A
Earnings DateN/A
Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • What’s The Deal Between MetaStat Inc. (MTST) And Celgene Corporation (CELG)?
    Insider Monkey8 months ago

    What’s The Deal Between MetaStat Inc. (MTST) And Celgene Corporation (CELG)?

    It was back in April when the Chief Medical Officer of pharma giant Celgene Corporation (NASDAQ:CELG), Dr. Jerome B. Zeldis joined the board of MetaStat Inc. (OTCMKTS:MTST). It was clear from here that something was in the works between the two companies and that perhaps a licensing deal would soon be struck between the two. […]

  • Zacks Small Cap Researchlast year

    MTST: Q3 Results, Initial Launch Expected in 2016

    The state licensure and CLIA certification follows on the heels of studies validating the performance and accuracy of MTST’s fully automated MetaSite Breast assay.  In late August MTST announced the automated (i.e.

  • Zacks Small Cap Research2 years ago

    MTSTD: Q2 Results, Meaningful Progress Towards Initial Launch

    The study, titled MenaCalc, a Quantitative Method of Metastasis Assessment, as a Prognostic Marker for Axillary Node-Negative Breast Cancer, assessed MenaCalc as a predictor of survival in patients with axillary node-negative (ANN) breast cancer.  Axillary lymph nodes are located in the armpit which is typically the first place where breast cancer will spread.  ANN means that the cancer has not spread to the lymph nodes which generally relates to a more favorable prognosis.  Tumor samples were obtained from eight Toronto hospitals where patients were treated from 1987 to 1993. Of the 403 patients, 332 had no lymphatic invasion while 70 did (data was missing on 1).